The name of the medicinal product, as referred to in Article 54, point (a) must also be expressed in Braille format on the packaging. The marketing authorisation holder shall ensure that the package information leaflet is made available on request from patients' organisations in formats appropriate for the blind and partially-sighted.
Art. 56a Directive (EU) 2001/83
In forcesince 26 Jan 2007
- 26 Jan 2007 – todayin force
- 30 Apr 2004 – 26 Jan 2007earlier wording
Versions are held from 6 Nov 2001; the article may be older.